Skip to content

BGI and Azerbaijan Thalassemia Middle signal co

BGI signs collaboration agreement in Azerbaijan

picture: Attendees from Azerbaijan Thalassemia Middle: Dr. Khuraman Jafarova, Chief Physician of Thalassemia Middle, Vice Director of Nationwide Hematology and Transfusion Middle; Dr. Afsana Mammadova, Head of Medical Diagnostics Laboratory, Supervisor of Biochemistry; Adam Najafli, MD, Head of Cytogenetics Laboratory, Medical Genetics Division; Dr. Agha Rza Aghayev, Head of Medical Genetics Division, Supervisor of Molecular Genetics
view extra

Credit score: BGI Genomics

On sixth September 2022, the Azerbaijan Thalassemia Middle and BGI held a digital signing ceremony to seal a Collaboration Settlement. The partnership goals to enhance thalassemia screening in Azerbaijan via genetic know-how.

In early 2021, every now and then of the “Prevention and Management of World Haemoglobinopathies” announcement, BGI Poverty Prevention and Management Panel clearly acknowledged they search to export China’s superior applied sciences for thalassemia to ‘Belt and Highway Initiative’ international locations, to collectively obtain complete thalassemia management within the world group.

In April 2022, BGI’s wholly-owned subsidiary, Huada Biotechnology (Wuhan) Co., Ltd, obtained the medical system registration certificates from the Nationwide Drug Administration for its alpha and beta thalassemia gene detection equipment (combining probe anchored polymerization sequencing methodology).

This settlement was signed by Dr. Valeh Hüseynov, the Govt Director of Nationwide Hematology and Transfusion Middle, Dr. Agha Rza Aghayev, the supervisor of Azerbaijan’s medical genetics division, and Mr. Jeremy Cao, the Vice President of BGI IntDx. The 2 organizations have entered a strategic partnership and can work collectively for a thalassemia examine analysis mission within the nation.

Dr Agha Rza Aghayev, Azerbaijan’s medical genetics division supervisor, had the next to say: “Thanks BGI for help and collaboration, I hope this analysis program will assist us to construct an efficient and well-designed methodology for screening Thalassemia.”

“Azerbaijan is likely one of the international locations with the best prevalence price of thalassemia,” mentioned Zhiyu Peng, BGI Genomics vp. “Our thalassemia gene detection testing combines cutting-edge excessive throughput sequencing platform and benefits of low value and complete detection. It helps scientific analysis partnership in methodology comparability, enhances new know-how collaboration within the scientific testing and discover the screening of thalassemia in Azerbaijan. BGI “additionally has a world hemoglobinopathy basis specializing in combating thalassemia worldwide, our objective is making the world a greater place with out this illness. BGI due to this fact proposes this settlement to reaffirm that we stand along with Azerbaijan’s thalassemia heart and its individuals.”

Mr Jeremy Cao, the Vice President of BGI IntDx, mentioned on the signing ceremony, “That is one in all our pioneer abroad thalassemia initiatives and such settlement commits us to work collectively extra carefully in direction of widespread targets, the pursuit of screening and management of thalassemia, and the imaginative and prescient that in a not too distant future there can be a world with out this illness.I want to say I’m assured that via our efforts and dedication, we can obtain extra and to proceed to develop even stronger relationships and friendships between the individuals of Azerbaijan and BGI.”

Thalassemia, an inherited blood dysfunction, brought on by the inadequate manufacturing of hemoglobin within the pink blood cells that ship oxygen and vitamins to all elements of the physique. Individuals with thalassemia have a lot much less hemoglobin than regular individuals and often undergo from gentle to extreme anemia.

The Azerbaijan Thalassemia Middle is the primary main public medical establishment combating thalassemia within the area. This Middle not solely gives service for sufferers who are suffering from this illness but additionally for individuals with different genetic situations. The nation additionally gives a basis offering medical providers to overseas residents at this Middle.

About BGI Genomics

BGI Genomics, headquartered in Shenzhen China, is a pioneer offering thalassemia genetic testing providers primarily based on next-generation sequencing (NGS) know-how since 2013. Increasing the supply of genetic testing has been instrumental within the screening, analysis and remedy of thalassemia.

Disclaimer: AAAS and EurekAlert! aren’t answerable for the accuracy of reports releases posted to EurekAlert! by contributing establishments or for using any data via the EurekAlert system.

Leave a Reply

Your email address will not be published.